Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data…
Whittier's Annual Roast to Toast Fundraiser on April 3rd, 2024 Will Support Health and Social Services for Boston's Most Vulnerable…
Interchangeability study for HADLIMA (adalimumab-bwwd) was conducted in accordance with the FDA’s Guidance for Industry; primary pharmacokinetics (PK) endpoints as…
WOBURN, MA / ACCESSWIRE / March 8, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of…
VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced…
CLARKSBURG, MD / ACCESSWIRE / March 7, 2024 / The American Society for Colposcopy and Cervical Pathology (ASCCP) is proud…
PITTSBURGH, March 7, 2024 /PRNewswire/ -- eHealth Technologies, a trailblazer in healthcare technology solutions for close to 20 years, has…
Clinical-stage CAR-T company is actively recruiting patients to evaluate SynKIR™-110, a new treatment candidate for ovarian cancer, mesothelioma, and cholangiocarcinoma…
Conference call and webcast: today, March 7, 2024, 9:00 am E.T. +1-888-407-2553 or +972-3- 9180608 I https://veidan.activetrail.biz/evogeneq4-2023 REHOVOT, Israel, March…
PROVIDENCE, R.I., March 7, 2024 /PRNewswire/ -- Next generation genomic tools company, Nabsys®, has executed a nonexclusive agreement with Canadian distributor,…
